# Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

> **NCT03284853** · PHASE3 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 436 (actual)

## Conditions studied

- Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Netarsudil/Latanoprost 0.02%/0.005%
- **DRUG:** GANFORT®

## Key facts

- **NCT ID:** NCT03284853
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-05
- **Primary completion:** 2020-11-06
- **Final completion:** 2020-11-06
- **Target enrollment:** 436 (ACTUAL)
- **Last updated:** 2022-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03284853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03284853, "Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03284853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*